An Open Trial to Assess the Tolerability of AVANZ® Salsola Immunotherapy (AV-X-02)

NCT02065856 Phase 2 COMPLETED

This trial is an open, national, multi-centre trial. The trial will be initiated in December 2013 and subjects will receive treatment for 6 weeks. Safety monitoring will be performed in an ongoing basis through a Clinical Safety Group with immediate access to Adverse Events registered in the clinical database. The composition, procedures and deliverables of the Clinical Safety Group will be detailed in a Safety Agreement prior to trial start.

Details

Lead sponsor	ALK-Abelló A/S
Phase	Phase 2
Status	COMPLETED
Enrolment	51
Start date	2013-12
Completion	2014-12

Conditions

• Allergic Rhinoconjunctivitis Due to Salsola Kali Pollen

Interventions

• AVANZ Salsola

Primary outcomes

• Frequency of patients with adverse reactions — Participants will be followed for an expected average of 6 weeks

Countries

Spain